Telodendrimer-based nanocarriers for the treatment of ovarian cancer

Author： Xiao Kai   Suby Nell   Li Yuanpei   Lam Kit S  

Publisher： Future Science

ISSN： 2041-5990

Source： Therapeutic Delivery, Vol.4, Iss.10, 2013-10, pp. : 1279-1292

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Current treatment for ovarian cancer

By Eltabbakh G.H.   Awtrey C.S.  

Expert Opinion on Pharmacotherapy, Vol. 2, Iss. 1, 2001-01 ,pp. : 109-124

Informa Healthcare

Access to resources Recommend Favorite

Treatment of platinum-resistant ovarian cancer

By Trimble Edward L   Wright John   Christian Michaele C  

Expert Opinion on Pharmacotherapy, Vol. 2, Iss. 8, 2001-08 ,pp. : 1299-1306

Informa Healthcare

Access to resources Recommend Favorite

Treatment options in the management of ovarian cancer

By Kikuchi Yoshihiro   Kita Tsunekazu   Takano Masashi   Kudoh Kazuya   Yamamoto Kenji  

Expert Opinion on Pharmacotherapy, Vol. 6, Iss. 5, 2005-05 ,pp. : 743-754

Informa Healthcare

Access to resources Recommend Favorite

Pemetrexed disodium in ovarian cancer treatment

By Morotti M   Valenzano Menada M   Venturini PL   Mammoliti S   Ferrero S  

Expert Opinion on Investigational Drugs, Vol. 21, Iss. 4, 2012-04 ,pp. : 437-449

Informa Healthcare

Access to resources Recommend Favorite

New developments in the treatment of ovarian cancer

By Wadler Scott  

Expert Opinion on Investigational Drugs, Vol. 10, Iss. 6, 2001-06 ,pp. : 1167-1172

Informa Healthcare

Access to resources Recommend Favorite